Weldon Mauney, MD
Neurology with Special Qualifications in Child Neurology · Gulf Breeze, FLNPI 1396915898
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,555 of the $7,523 with a category attached, or 73.8%. 30 manufacturers reported payments, led by H. Lundbeck A S at 25.9% of the total. Reporting peaked in 2024 at $3,382 and has fallen 65.5% since, to $1,166 in 2025.
Across 221 payments — averaging $34.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- H. Lundbeck A S$2K
- UCB, Inc.$1K
- Jazz Pharmaceuticals Inc.$456
- Merz Pharmaceuticals, LLC$326
- Acadia Pharmaceuticals Inc$278
- AbbVie$278
- plus $3K from 24 others
Across 237 payments — averaging $5430.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sarepta Therapeutics, Inc.$677K
- Amgen$224K
- Eli Lilly$79K
- H. Lundbeck A S$60K
- Zogenix Inc.$54K
- PTC Therapeutics, Inc.$44K
- plus $147K from 6 others
What the payments were for
- Travel & lodging$1,95126%
- Food & beverage$5,55574%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| H. Lundbeck A S | 4 | $1,951 |
| UCB, Inc. | 66 | $1,492 |
| Jazz Pharmaceuticals Inc. | 16 | $456 |
| Merz Pharmaceuticals, LLC | 10 | $326 |
| Acadia Pharmaceuticals Inc | 11 | $278 |
| AbbVie(2 entities) | 15 | $278 |
| Livanova USA, Inc. | 10 | $277 |
| Eisai Inc. | 14 | $265 |
| Neurelis, Inc. | 6 | $246 |
| Biogen | 11 | $239 |
| Immedica Pharma US, Inc. | 5 | $239 |
| Catalyst Pharmaceuticals, Inc. | 11 | $230 |
| Genentech USA, Inc. | 8 | $156 |
| SK Life Science, Inc. | 3 | $155 |
| Biocodex, Inc. | 5 | $135 |
| Greenwich Biosciences, Inc. | 1 | $106 |
| Aquestive Therapeutics, Inc. | 1 | $95 |
| Saol Therapeutics Inc. | 2 | $95 |
| ITF Therapeutics LLC | 3 | $87 |
| Otter Pharmaceuticals, LLC | 2 | $70 |
| Pyros Pharmaceuticals, Inc. | 3 | $62 |
| Medtronic | 2 | $46 |
| Zogenix Inc. | 2 | $42 |
| Amneal Pharmaceuticals LLC | 2 | $40 |
| Ipsen Biopharmaceuticals, Inc | 2 | $38 |
| Piramal Critical Care | 2 | $31 |
| Upsher-smith Laboratories LLC | 1 | $31 |
| NS Pharma, Inc. | 1 | $29 |
| Soleno Therapeutics, Inc. | 1 | $17 |
| Biomarin Pharmaceutical Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,523 in reported general payments places this provider in the 65th percentile of 137 neurology with special qualifications in child neurology providers in Florida.
See all neurology with special qualifications in child neurology providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology with special qualifications in child neurology in Gulf Breeze
- James RenfroeGulf Breeze$61K
- Paul WinnerWest Palm Beach$624K
- Omer Abdul HamidOrlando$283K
- Natalie GillsonFort Myers$250K
- Trevor ResnickMiami$230K
- Migvis MonduyMiami$188K
- Elza VasconcellosMiami$170K
- Ronald DavisWinter Park$154K
- Ian MillerMiami$104K
- Michael HammerSaint Petersburg$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.